EvoHealth

09/01/2026

PCOS is increasingly being recognized as more than a reproductive disorder.

Newer research is reinforcing what we see clinically: many patients have a broader endocrine and metabolic phenotype involving insulin resistance, androgen excess, ovulatory dysfunction, adiposity, and cardiometabolic risk.

That matters because PCOS should not automatically trigger the same supplement or nutrition protocol for every patient.

The better functional-medicine approach is to identify the dominant phenotype, use validated markers to define what is actually abnormal, and then target the intervention accordingly.

Personalized care should mean phenotype-driven care, not simply more testing and more supplements.

08/17/2026

Meet Bri Cole, DNP, APRN — a key part of the EvoHealth team helping patients take a more proactive, personalized approach to their health.

At EvoHealth, Bri provides Direct Primary Care, hormone optimization, weight-management support, and ongoing health guidance, with an emphasis on individualized, evidence-informed care rather than a one-size-fits-all approach.

Whether the goal is improving energy, optimizing hormones and metabolic health, addressing weight concerns, or simply having a provider who has the time to actually know you, Bri helps create a more accessible and personalized healthcare experience.

Healthcare, evolved.

07/27/2026

At EvoHealth, we specialize in root-cause healthcare, optimizing human performance, and helping clients extend both lifespan and healthspan through personalized, proactive care.

Our model integrates systems biology, comprehensive biomarker analysis, advanced laboratory testing, targeted nutrition, lifestyle-based interventions, personalized hormone therapy, and evidence-informed longevity strategies.

By evaluating how the body’s systems interact, we work to identify underlying imbalances and develop individualized plans focused on root-cause health, precision prevention, performance optimization, and healthy aging.

Because healthcare should not begin only after disease develops.

It should be personalized, proactive, and designed to help you feel better today while building the foundation to thrive for decades to come.

Healthcare, Evolved.
Feel Better Today. Thrive Tomorrow.

📍 13801 Metcalf Ave, Overland Park, KS
💻 Telehealth available throughout Kansas & Missouri

07/15/2026

Most people know their cholesterol. Far fewer know their Lp(a)—despite it being one of the strongest genetically determined cardiovascular risk factors.

The challenge is that you can have an excellent lifestyle, normal LDL-C, and still carry a significantly elevated lifetime cardiovascular risk if your Lp(a) is high. Because Lp(a) is largely inherited and remains stable throughout life, a one-time measurement is sufficient for most people.

The good news? Identifying elevated Lp(a) doesn’t mean you’re destined to develop heart disease. It provides valuable information that can help personalize your overall prevention strategy, including more aggressive management of modifiable risk factors when appropriate. With several targeted Lp(a)-lowering therapies currently in phase 3 clinical trials, knowing your level may become even more important in the coming years.

06/30/2026

06/22/2026

If you ask 10 people what’s causing IBS, you’ll probably get 10 different answers.

Stress. Food sensitivities. The microbiome.

The problem? IBS is rarely that simple.

For years, it was viewed as a simple digestive disorder. Today, research published in leading gastroenterology journals, including Gastroenterology and The Lancet Gastroenterology & Hepatology, suggests IBS is a complex disorder of gut-brain interaction involving the nervous system, immune system, microbiome, and gastrointestinal tract.

Several mechanisms appear to contribute. One of the most well-established is visceral hypersensitivity, where normal amounts of intestinal gas or stretching are perceived as pain. Research has also highlighted gut-brain axis dysfunction, altered intestinal permeability (“leaky gut”), microbial imbalances, immune activation, and changes in gut motility and neurotransmitter signaling.

This helps explain why two patients with IBS can have completely different symptoms, and why there is rarely a single root cause.

IBS is not simply a stress disorder, nor is it just a gut disorder. It is a multifactorial condition involving complex interactions between the gut, brain, immune system, and microbiome. Understanding these underlying mechanisms is often the first step toward a more personalized and effective treatment strategy.

06/19/2026

GLP-1 receptor agonists may ultimately prove to be far more than weight-loss medications.

While weight reduction receives most of the attention, studies consistently demonstrate improvements across numerous physiologic systems that extend beyond the scale:

• Blood pressure reduction (~4–8 mmHg in many trials)
• Improvements in insulin sensitivity and hyperinsulinemia
• Lower systemic inflammation (hs-CRP, inflammatory cytokines)
• Reduced visceral and ectopic fat accumulation
• Improvement in metabolic dysfunction-associated fatty liver disease (MASLD)
• Reduced progression to type 2 diabetes in high-risk individuals
• Improved endothelial function and vascular health
• Favorable effects on heart failure symptoms and outcomes
• Reduction in major adverse cardiovascular events (MACE)
• Meaningful improvements in obstructive sleep apnea severity
• Potential reductions in chronic kidney disease progression
• Decreased food noise and improved appetite regulation through central nervous system pathways

What makes GLP-1s particularly intriguing in the longevity space is their ability to influence multiple hallmarks of cardiometabolic aging simultaneously. Rather than targeting a single biomarker, they appear to favorably affect adiposity, glycemic control, inflammation, vascular function, blood pressure, and organ-specific fat deposition at the same time.

That doesn’t mean they’re a longevity drug. We do not yet have evidence that GLP-1s extend human lifespan. However, many of the pathways most strongly associated with age-related disease appear to move in a favorable direction.

The most interesting question may not be how much weight these medications help people lose, but whether improving so many interconnected biologic systems ultimately translates into a longer period of health, function, and resilience as we age.